406 related articles for article (PubMed ID: 24634471)
41. Inactivation of the Cullin (CUL)-RING E3 ligase by the NEDD8-activating enzyme inhibitor MLN4924 triggers protective autophagy in cancer cells.
Luo Z; Pan Y; Jeong LS; Liu J; Jia L
Autophagy; 2012 Nov; 8(11):1677-9. PubMed ID: 22874562
[TBL] [Abstract][Full Text] [Related]
42. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
[No Abstract] [Full Text] [Related]
43. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
[TBL] [Abstract][Full Text] [Related]
44. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
[TBL] [Abstract][Full Text] [Related]
45. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.
Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S; Vire B; Gibellini F; Njuguna N; Lee E; Stennett L; Raghavachari N; Liu P; McCoy JP; Raffeld M; Stetler-Stevenson M; Yuan C; Sherry R; Arthur DC; Maric I; White T; Marti GE; Munson P; Wilson WH; Wiestner A
Blood; 2011 Jan; 117(2):563-74. PubMed ID: 20940416
[TBL] [Abstract][Full Text] [Related]
46. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
47. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
48. Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells.
Pickering BM; de Mel S; Lee M; Howell M; Habens F; Dallman CL; Neville LA; Potter KN; Mann J; Mann DA; Johnson PW; Stevenson FK; Packham G
Oncogene; 2007 Feb; 26(8):1166-77. PubMed ID: 16924235
[TBL] [Abstract][Full Text] [Related]
49. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun SY; Boise LH; Lonial S
Blood; 2014 May; 123(21):3269-76. PubMed ID: 24713927
[TBL] [Abstract][Full Text] [Related]
50. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG.
Ghosh AK; Kay NE; Secreto CR; Shanafelt TD
Clin Cancer Res; 2009 Feb; 15(4):1250-8. PubMed ID: 19228728
[TBL] [Abstract][Full Text] [Related]
51. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL.
Chen Y; Peubez C; Smith V; Xiong S; Kocsis-Fodor G; Kennedy B; Wagner S; Balotis C; Jayne S; Dyer MJS; Macip S
J Cell Mol Med; 2019 Jan; 23(1):340-348. PubMed ID: 30353642
[TBL] [Abstract][Full Text] [Related]
52. HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
Xiao K; Yang L; Gao X; An Y; Xie W; Jingquan G
Biomed Res Int; 2020; 2020():1481572. PubMed ID: 32908868
[TBL] [Abstract][Full Text] [Related]
53. p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
López-Guerra M; Roué G; Pérez-Galán P; Alonso R; Villamor N; Montserrat E; Campo E; Colomer D
Clin Cancer Res; 2009 Apr; 15(8):2767-76. PubMed ID: 19351760
[TBL] [Abstract][Full Text] [Related]
54. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
55. Neddylation-Independent Activities of MLN4924.
Mao H; Sun Y
Adv Exp Med Biol; 2020; 1217():363-372. PubMed ID: 31898238
[TBL] [Abstract][Full Text] [Related]
56. High Efficiency Apoptosis Induction in Breast Cancer Cell Lines by MLN4924/2DG Co-Treatment.
Oladghaffari M; Islamian JP; Baradaran B; Monfared AS; Farajollahi A; Shanehbandi D; Mohammadi M
Asian Pac J Cancer Prev; 2015; 16(13):5471-6. PubMed ID: 26225696
[TBL] [Abstract][Full Text] [Related]
57. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
58. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
59. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
[TBL] [Abstract][Full Text] [Related]
60. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
